Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02345265 · ClinicalTrials.gov registry record · Phase 2

Testing the Combination of the Study Drugs Cediranib and Olaparib in Recurrent Ovarian Cancer

A Phase 2 study of Ovarian Carcinoma and Primary Peritoneal Carcinoma, sponsored by National Cancer Institute (NCI).

Active
Registry status
Phase 2
Development phase
70
Enrollment target
20
Study locations

NCT02345265: Active Phase 2 study of Ovarian Carcinoma and Primary Peritoneal Carcinoma, sponsored by National Cancer Institute (NCI).

NCT02345265 is a Phase 2 study of Ovarian Carcinoma and Primary Peritoneal Carcinoma that is active but no longer recruiting, run by National Cancer Institute (NCI). The registered enrollment target is 70 participants, below the 3,242-participant average among 35 other Ovarian Carcinoma trials with a reported enrollment target (98% lower). The trial reports 20 study locations across 10 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02345265, a Phase 2 study of Ovarian Carcinoma and Primary Peritoneal Carcinoma, is active but no longer recruiting, sponsored by National Cancer Institute (NCI).

ACTIVE NOT RECRUITING
Registry status
Phase 2
Development phase
70 participants
Enrollment target
20
Study locations

Study Summary

This phase II trial studies how well olaparib and cediranib maleate work in treating patients with ovarian, primary peritoneal, or fallopian tube cancer that has come back after a period of improvement (recurrent). Olaparib and cediranib maleate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

Primary Outcome

PFS determined per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1), where disease progression represents at least a 20% increase in the sum of diameters of target lesions, appearance of one or more new lesions, or unequivocal progression of existing non-target lesions. Homologous recombination repair (HRR) status was measured by the BROCA-HR assay. BROCA-HR is a targeted NGS platform including all known gynecologic cancer susceptibility genes and other DNA repair or related

Conditions Studied

Ovarian Carcinoma Primary Peritoneal Carcinoma Fallopian Tube Carcinoma Fallopian Tube Endometrioid Adenocarcinoma Ovarian High Grade Serous Adenocarcinoma Fallopian Tube Serous Adenocarcinoma Primary Peritoneal Endometrioid Adenocarcinoma Primary Peritoneal Serous Adenocarcinoma Ovarian High Grade Endometrioid Adenocarcinoma

Interventions

  • PROCEDURE Biospecimen Collection
  • PROCEDURE Computed Tomography
  • PROCEDURE Biopsy Procedure
  • PROCEDURE Echocardiography Test
  • DRUG Cediranib Maleate

Study Locations (20)

California

  • City of Hope Comprehensive Cancer Center - Duarte
  • Los Angeles General Medical Center - Los Angeles
  • USC / Norris Comprehensive Cancer Center - Los Angeles
  • Keck Medical Center of USC Pasadena - Pasadena

Maryland

  • Johns Hopkins University/Sidney Kimmel Cancer Center - Baltimore
  • National Institutes of Health Clinical Center - Bethesda
  • NCI - Center for Cancer Research - Bethesda

Massachusetts

  • Massachusetts General Hospital Cancer Center - Boston
  • Brigham and Women's Hospital - Boston
  • Dana-Farber Cancer Institute - Boston

Arizona

  • Mayo Clinic Hospital in Arizona - Phoenix
  • Mayo Clinic in Arizona - Scottsdale

Florida

  • Mayo Clinic in Florida - Jacksonville
  • Moffitt Cancer Center - Tampa

New Jersey

  • Rutgers Cancer Institute of New Jersey-Robert Wood Johnson University Hospital - New Brunswick
  • Rutgers Cancer Institute of New Jersey - New Brunswick

Minnesota

  • Mayo Clinic in Rochester - Rochester

North Carolina

  • Duke University Medical Center - Durham

Trial Details

FieldValue
Enrollment Target 70 participants
Start Date 2016-05-23
Est. Completion 2026-11-25
Phase Phase 2
National Cancer Institute (NCI)

3,257 total trials

What the registry record for NCT02345265 still lists

NCT02345265 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 70 participants, a relatively small participant target, below the 3,242-participant average among 35 other Ovarian Carcinoma trials with a reported enrollment target (98% lower).

The record links to 9 conditions, with Ovarian Carcinoma appearing as the primary indexed condition, and to 5 interventions - of which Biospecimen Collection is the first listed.

NCT02345265 names 20 study sites across 10 states, led by California, Maryland, Massachusetts.

Frequently Asked Questions

What is clinical trial NCT02345265 about?

NCT02345265 is a clinical study titled "Testing the Combination of the Study Drugs Cediranib and Olaparib in Recurrent Ovarian Cancer". This phase II trial studies how well olaparib and cediranib maleate work in treating patients with ovarian, primary peritoneal, or fallopian tube cancer that has come back after a period of improvement (recurrent). Olaparib and cediranib maleate may stop the growth of tumor cells by blocking some of...

What is the current status of trial NCT02345265?

This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 70 participants. The study started on 2016-05-23. Estimated completion is 2026-11-25.

What conditions does trial NCT02345265 study?

This clinical trial studies the following conditions: Ovarian Carcinoma, Primary Peritoneal Carcinoma, Fallopian Tube Carcinoma, Fallopian Tube Endometrioid Adenocarcinoma, Ovarian High Grade Serous Adenocarcinoma.

What interventions are being tested in trial NCT02345265?

The interventions under investigation include: Biospecimen Collection (PROCEDURE), Computed Tomography (PROCEDURE), Biopsy Procedure (PROCEDURE), Echocardiography Test (PROCEDURE), Cediranib Maleate (DRUG).

Who is sponsoring clinical trial NCT02345265?

This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02345265 being conducted?

This trial has 20 study locations across Arizona, California, Florida, Maryland, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Ovarian Carcinoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT02345265's enrollment target sits among peer trials

70 21st of 35 higher than 14 of 35 other Ovarian Carcinoma trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Ovarian Carcinoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00969111 · 70 participants · NA

    Postoperative or Salvage Radiotherapy (RT) for Node Negative Prostate Cancer Following Radical Prostatectomy

  • NCT01712620 · 70 participants · Phase 2

    Spironolactone for Pulmonary Arterial Hypertension

  • NCT02143830 · 70 participants · Phase 2

    HSCT for Patients With Fanconi Anemia Using Risk-Adjusted Chemotherapy

  • NCT02601339 · 70 participants

    NIRS Monitoring in Premature Infants

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Related registry views

Source: ClinicalTrials.gov NCT02345265, the US trial registry maintained by the National Library of Medicine. NCT02345265 (small enrollment · wide site footprint · active not recruiting) retrieved and formatted by PlainTrial, see methodology.